Zynerba Pharma (ZYNE) Tops Q3 EPS by 2c
- Wall Street falls as bank, healthcare shares weigh
- Qualcomm (QCOM) Faces U.S. Antitrust Case Over Licensing - Bloomberg
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Zynerba Pharma (NASDAQ: ZYNE) reported Q3 EPS of ($0.67), $0.02 better than the analyst estimate of ($0.69).
For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley (MS) Tops Q4 EPS by 17c
- Mizuho Securities Raises Price Target on Noble Energy (NBL) to $48; Reiterates Buy
- RPM International (RPM) Acquires Prime Resins
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!